PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q94181

Takeyuki SUGIURA

Appln. No.: 10/573,969

Group Art Unit: 1652

Confirmation No.: 9936

Examiner: Iqbal Hossain CHOWDHURY

Filed: March 30, 2006

For: TETRAHYDROFOLATE SYNTHETASE GENE

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This response is in regard to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES, dated August 6, 2007, issued in the above-referenced patent application (copy attached).

In the Notice to Comply, the Examiner states that the present application fails to comply with the requirements of 37 C.F.R. §§1.821-1.825 for the following reasons:

The application fails to comply with the requirements of 37 C.F.R. § 1.821-1.825.

The application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. § 1.821(c).

STATEMENT TO SUPPORT FILING

U.S. Application No.: 10/573,969

Attorney Docket No.: Q94181

A copy of the "Sequence Listing" in computer readable form has not been submitted as

required by 37 C.F.R. § 1.821(e).

Applicants enclose herewith a substitute Sequence Listing, in paper and computer-

readable form copies, that fully addresses the issues raised in the Notice to Comply.

Applicants assert that this Response to the Notice to Comply and the enclosures are being

timely filed, and that the enclosures bring the present application in full compliance with the

requirements of 37 C.F.R. §§1.821-1.825.

Applicants respectfully request that the Examiner acknowledge that the substitute

Sequence Listing meets the requirements of 37 C.F.R. §§1.821-1.825 and that the Examiner

enter the substitute Sequence Listing.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: August 31, 2007

4





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P. Do. 1450
Alexandria, Virginia 223 13-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	AT	TORNEY DOCKET NO.	CONFIRMATION NO.	
10/573,969	03/30/2006	Takeyuki Sugiura		Q94181	9936	
65565 SUGHRUE-26	7590 08/06/2007 55550			EXAMINER		
2100 PENNSYLVANIA AVE. NW WASHINGTON, DC 20037-3213			· ·	CHOWDHURY, IQBAL HOSSAIN		
				ART UNIT	PAPER NUMBER	
				1652		
			MAIL DATE	DELIVERY MODE		
			08/06/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

	visions of 37 CFR 1.136(a)).
The	e nucleotide and/or amino acid sequence disclosure contained in this application does not comply with requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
\	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
☒	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
☒	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
Ar	7. Other: the claims include sequences greater than 4 amino acids that do not have a SEQ ID NO. oplicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
⊠ sp	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment ecifically directing its entry into the application.
	A statement that the content of the paper and computer readable copies are the same and, where plicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 325(d).
Fo	or questions regarding compliance to these requirements, please contact:
Fo	or Rules Interpretation, call (703) 308-4216 or (703) 308-2923 or CRF Submission Help, call (703) 308-4212 or 308-2923 extentIn Software Program Support
	Technical Assistance 703-287-0200 To Purchase Patentin Software 703-306-2600
	I O I MI OLIMOO I OLOGIANI O OLOGIANI OLOGIANI OLOGIANI OLOGIANI OLOGIANI

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

APPLICATION NO. /CONTROL NO. 10/573,969	FILING DATE 03/30/2006	FIRST NAMED INVENTOR / PATENT IN REEX. Sugiura, Takeyuki	AMINATION	ATTORNEY DOCKET NO. Q94181	
			EXAMINER Chowdhury, Iqbal H		
		·			
			ARŢ UNIT	PAPER	
			1652		

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. For example, the claims recite SEQ ID NO: 1, 2, 3, 4, 5, and 6, however, no CRF has been submitted. (See attached notice to comply).

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to lqbal Chowdhury whose telephone number is (574) 272-8137. The examiner can normally be reached on Monday-Friday from 9:00am to 5:00pm.

reached on 703-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

Iqbal Chowdhury, PhD, Patent Examiner Art Unit 1652 (Recombinant Enzymes) US Patent and Trademark Offic Rm. REM 2B69, Mail Box. 2C70 Ph. (571)-272-8137, Fax. (571)-273-8137

> PONNATHAPUACHUTAMURTHY SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1500